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Abstract 
Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mel-
litus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodium-glucose cotransporter 2 (SGLT2) 
induces glycosuria, reduces glucose toxicity and improves insulin sensitivity and β-cell function. As the mechanism of 
action of SGLT2 inhibitors is different from other agents and completely insulin-independent, the use of these drugs 
might potentially be efficacious alone or in combination with any other antidiabetic drug, including insulin. Dapa-
gliflozin is a highly selective and reversible SGLT2 inhibitor approved for use in adult patients with T2DM as mono-
therapy in patients intolerant of metformin or as adjunctive therapy in patients inadequately controlled on existing 
antidiabetic medications, including insulin. A literature search conducted using PubMed identified key publications 
related to the use of dapagliflozin in the treatment of patients with diabetes mellitus. No date limits were applied. This 
review focuses on the safety and efficacy of this SGLT2 inhibitor. Dapagliflozin produces dose-related reductions in 
glycosylated hemoglobin (HbA1c) as monotherapy and as add-on to other antidiabetic agents, with significant reduc-
tions in body weight. Hypoglycemia is uncommon. Preliminary data from a phase 2 pharmacokinetic/pharmacody-
namic study suggest that dapagliflozin may also improve glycemic control in patients with type 1 diabetes mellitus. 
Clinical trials published to date show that dapagliflozin is safe and effective as monotherapy or as an add-on to insulin 
or oral antidiabetic agents in patients with T2DM.
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Background
The pathophysiology of type 2 diabetes mellitus (T2DM) 
is complex and multifaceted. The core defects of T2DM 
include quantitative and qualitative β-cell dysfunc-
tion, peripheral (skeletal muscle) insulin resistance, 
and elevated glucose production in the liver, as well as 
increased lipolysis when obesity is present. However, 
it is becoming accepted that other known mechanisms, 
including increased glucagon, decreased incretin effect, 
increased glucose reabsorption in the kidneys and some 
neurotransmitter dysfunction, are also involved in the 
pathophysiology of T2DM [1].
The currently available antidiabetic agents have been 
developed to target one or more of the underlying defects 
or processes involved in T2DM [2]. Generally, glycemic 
control in patients with T2DM is poor, with only approx-
imately 53  % of patients achieving glycemic goals with 
their current treatment regimen [3].
However, even in patients with good glycemic con-
trol, the progressive nature of T2DM means that most 
patients will eventually require multiple antidiabetic 
medications to manage their disease [4]. As a result, there 
remains a need for new drug development in the field.
This review discusses one of the most recently dis-
covered classes of antidiabetic agents, the inhibitors of 
the sodium-glucose cotransporter 2 (SGLT2). SGLT2 
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inhibitors currently approved or under investigation 
include dapagliflozin, canagliflozin, empagliflozin and 
ipragliflozin; this manuscript will focus on the efficacy 
and safety of the highly selective and reversible SGLT2 
inhibitor dapagliflozin, primarily in patients with T2DM.
Search strategy
A literature search was conducted using the PubMed data-
base to identify key papers related to human studies of 
dapagliflozin in the treatment of patients with diabetes mel-
litus. Various combinations of key terms, including “type 2 
diabetes”; “type 1 diabetes”; “SGLT2” or “sodium-coupled 
glucose cotransporter 2” “monotherapy”; “add-on or com-
bination”; and “dapagliflozin”, were used, with no date limits 
applied. The search focused on clinical trials, relevant sub-
studies of clinical trials identified, meta-analyses and sys-
tematic reviews. Additional papers were included from the 
reference lists of relevant articles sourced from the search. 
Recent guidelines and consensus documents were also 
considered for inclusion. The initial search was updated to 
include articles published up to March 27, 2015.
The role of the kidney in glucose reabsorption
The kidneys have a major role in glucose regulation in 
humans; under normal circumstances, over 99 % of the glu-
cose filtered by the glomeruli is reabsorbed in the proximal 
tubules [5, 6], such that virtually no glucose is excreted in 
the urine. Renal glucose reabsorption is achieved through 
the action of the SGLT family of protein transporters, pri-
marily SGLT1 and SGLT2 [6]. These proteins transport 
glucose across the membranes of the proximal tubule epi-
thelial cell in an active process that involves sodium trans-
port, facilitated by the sodium gradient between the tubule 
and the cell, which supports secondary active co-transport 
of glucose. Glucose then passively diffuses into the intercel-
lular space mainly via the GLUT2 (glucose transporter 2), a 
member of the GLUT family of proteins [6, 7].
In individuals without T2DM, SGLT2 is responsible for 
the majority (80–90 %) of renal glucose reabsorption [6, 
8]. When the concentration of glucose in plasma exceeds 
that which can be reabsorbed via the SGLT proteins, 
the excessive amount of glucose is excreted in the urine 
[7, 9]. Furthermore, data from animal models of diabe-
tes and from preclinical human models suggest that the 
hyperglycemic state in T2DM is associated with signifi-
cantly increased expression of SGLT2 and GLUT2 pro-
teins, together with an increased level of renal glucose 
reabsorption [7, 10]. Therefore, SGLT2 is a novel thera-
peutic target for antidiabetic therapy.
The role of glycosuria in glucotoxicity
The harmful metabolic effects of chronic hyperglycemia 
associated with the two core defects of T2DM, insulin 
resistance and partial β-cell failure, can be described as 
“glucose toxicity”, which contributes in turn to further 
progression of β-cell dysfunction in a vicious cycle of glu-
cose toxicity-induced pathogenesis [11, 12]. Thus, tight 
glycemic glucose control is, in part, considered essential 
to reverse or slow the glucotoxic effects of chronic hyper-
glycemia on the β-cells [4].
Glycosuria occurs when the maximal reabsorptive 
capacity of the glucose transport system in the kidney 
becomes saturated, above or just below the theoretical 
plasma glucose threshold of approx 11 mmol/L (198 mg/
dL); both the threshold and the transport maximum of 
glucose are higher in patients with diabetes mellitus [8]. 
Conversely, induction of glycosuria without affecting 
other metabolic parameters has been shown to reduce 
elevated plasma glucose levels, supporting the hypothesis 
that glucose toxicity contributes to β-cell dysfunction in 
patients with T2DM and that reversing glucose toxicity 
via “therapeutic glycosuria” may improve insulin sensitiv-
ity and β-cell function [11, 13, 14].
Sodium‑glucose cotransporter 2 inhibitors
Renal tubule regulation of glucose reabsorption by the 
kidney in the non-diabetic individual is shown in Fig. 1. 
Inhibition of SGLT2 results in a lowering of the thresh-
old for renal glucose excretion and an increase in urinary 
glucose excretion, with an associated reduction in plasma 
glucose levels and the potential to decrease glucose toxic-
ity with chronic administration [7, 15–17]. The action of 
SGLT2 inhibitors is glucose-dependent, becoming neg-
ligible when plasma glucose concentration drops below 
90/mg/dL, so the risk of hypoglycemia is lower than with 
insulin-dependent antidiabetic drugs [18].
Evidence suggests that glycosuria induced by SGLT2 
inhibitors can also significantly improve β-cell insulin 
secretion and insulin sensitivity in peripheral tissues, 
associated with a reduction in plasma glucose concentra-
tion [13, 14, 16, 17, 19]. In addition, SGLT2 inhibitors as a 
class offer the clinical benefits of promoting body weight 
loss and produce a modest reduction in both systolic and 
diastolic blood pressure [16–18, 20–26].
The mechanisms of action of the blood pressure lower-
ing effects of SGLT2 inhibitors are not fully understood. 
However, they are likely due to a mild osmotic diuretic 
effect in association with reductions in body weight and 
increased hematocrit, although it is possible that there 
may be a contribution from local inhibition of the renin-
angiotensin system secondary to enhancement of sodium 
delivery to the juxtaglomerular apparatus [20, 23, 27]. 
Orthostatic hypotension is not increased with SGLT2 
inhibitors.
Weight loss associated with SGLT2 inhibitors is biphasic, 
with an initial reduction in total body weight which can be 
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attributed to fluid loss and a subsequent gradual continu-
ous reduction resulting from increased urinary glucose 
excretion with associated loss of calories [14, 17, 18, 22]. 
Body composition assessment using dual-energy X-ray 
absorptiometry and magnetic resonance imaging analysis 
in patients with T2DM treated with dapagliflozin showed 
that the reduction in total body weight was predominantly 
via reductions in total body fat mass, visceral adipose tis-
sue and subcutaneous adipose tissue volume [28].
The effects of SGLT2 inhibitors on hyperglycemia, body 
weight, and blood pressure suggest a favorable effect on 
cardiovascular risk factors. However, data on long-term 
effects on major cardiovascular outcomes, including myo-
cardial infarction, stroke, and other vascular endpoints, 
are for the most part still under investigation, with results 
expected over the next few years [16, 22, 26]. Results of 
studies available to date show that empagliflozin amelio-
rated cardiovascular injury, coronary artery remodeling, 
and vascular dysfunction in a T2DM model in obese mice, 
suggesting a possible role in preventing diabetic macro-
vascular and microvascular complications [29], and did 
not prolong the QT interval in healthy volunteers [30]. 
Empagliflozin was also associated with a decline in arte-
rial stiffness, a marker for renal and cardiovascular clinical 
outcomes, in young patients with type 1 diabetes mellitus 
(T1DM) [21]. While this review was under revision, Zin-
man et al. published in the New England Journal of Medi-
cine the results of the EMPA-REG OUTCOME Study 
[31], demonstrating the achievement of the pre-defined 
primary endpoint (3-point reduction of MACE). Among 
the different effects of empagliflozin (and of all SGLT2 
inhibitors), none appeared to be specifically responsible 
for the significant reduction of cardiovascular events. This 
suggests that such CV protection might be assumed as a 
class effect, but firm evidence for this assumption will not 
be available before 2017–2019 (https://clinicaltrials.gov/
ct2/show/record/NCT01032629, https://clinicaltrials.
gov/ct2/show/NCT01730534).
SGLT2 inhibitors as a class have generally been shown 
to be as effective as other antidiabetic agents, with a good 
safety profile [18, 32]. Data from phase II/III clinical tri-
als, pooled analyses of randomized controlled trials, and 
systematic reviews show that SGLT2 inhibitors are as 
effective as other antidiabetic agents such as metformin, 
sulfonylureas, or dipeptidyl peptidase-4 (DPP-4) inhibi-
tors in head-to-head trials, and may offer better long-
term glucose-lowering efficacy [16–18, 24, 32, 33].
The risk of hypoglycemia is lower with SGLT2 inhibi-
tors than with conventional antidiabetic agents, but there 
is a higher risk of genital infections (mostly mycoses on 
Fig. 1 Glucose reabsorption by the normal kidney, showing the site of action of sodium-glucose cotransporter (SGLT) 2 inhibitors. Modified with 
permission from Chao and Henry [7]
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the external genitals) [16–18, 22, 24, 26, 32]. The effects 
of SGLT2 inhibitors on macrovascular and microvascu-
lar outcomes are yet to be determined in human studies; 
however, adding SGLT2 inhibitors, and specifically dapa-
gliflozin, to the standard of care was recently projected to 
reduce cardiovascular and microvascular complications 
associated with T2DM, in a human model study using 
simulation methodology [34].
The efficacy of SGLT2 inhibitors is influenced by the 
level of hyperglycemia and renal function [18, 22, 27]. 
Patients with substantial levels of hyperglycemia have a 
greater level of urinary glucose excretion and plasma glu-
cose reduction. Conversely, patients with a lower glomer-
ular filtration rate have a lower level of urinary glucose 
excretion, which is likely to lead to a lesser glucose-low-
ering effect [35]. Long-term study of patients with T2DM 
and moderate renal impairment showed that, although 
dapagliflozin reduced weight and blood pressure, glyce-
mic control was not improved.
Dapagliflozin in type 2 diabetes mellitus
Dapagliflozin is indicated for patients aged 18 years and 
over with T2DM for use as monotherapy to improve gly-
cemic control in patients with inadequate glycemic con-
trol who are intolerant to metformin, and as an adjunct 
to diet and exercise in combination with other glucose-
lowering medicinal agents in patients inadequately con-
trolled on existing antidiabetic medications, including 
insulin [36].
In patients with moderate renal impairment [creatinine 
clearance <60  mL/min or estimated glomerular filtra-
tion rate (eGFR) <60 mL/min/1.73 m2] dapagliflozin has 
been shown to be less effective. Therefore, dapagliflozin 
is not recommended for use in patients with moderate to 
severe renal impairment. Such limitations have not been 
introduced for the presence of side effects, but in recog-
nition of reduced efficacy in this patient population.
The efficacy and safety of dapagliflozin as monotherapy 
and as add-on/combination therapy with existing anti-
diabetic treatment in patients with diabetes mellitus has 
been established in a series of phase II and III trials in 
the clinical development program and is supported by 
five recently published comprehensive reviews or meta-
analyses [37–41]. It should be noted that, while different 
dosages of dapagliflozin were evaluated in the above-
mentioned trials, the only dosage currently approved in 
Europe is 10 mg in oral administration once daily.
Efficacy as monotherapy
Dapagliflozin has been shown to be effective in sev-
eral large (n  >  261), randomized, double-blind, pla-
cebo-controlled studies of 12 or 24  weeks’ duration in 
treatment-naïve patients with T2DM [25, 42–46]. Dapa-
gliflozin was evaluated at doses ranging from 1 to 50 mg 
once daily when added to background diet and exercise 
[42–44]; compared with metformin monotherapy [45, 
47]; or administered as monotherapy in both treatment-
experienced and treatment-naïve patients [25].
Dapagliflozin monotherapy demonstrated dose-related 
reductions from baseline in glycosylated hemoglobin 
(HbA1c) in all dapagliflozin groups, ranging from mean 
reductions of −0.55 to −1.45  % overall [25, 42–46] 
(Table  1). Statistically significant reductions in fasting 
plasma glucose (FPG) and body weight for dapagliflozin 
versus placebo or metformin were observed. Hypogly-
cemia was uncommon in dapagliflozin-treated patients; 
genital and urinary tract infections were more common 
in dapagliflozin groups than in controls.
Dapagliflozin monotherapy was generally as effective as 
metformin monotherapy [47, 48], and the glycemic effi-
cacy and reduction in weight of dapagliflozin monother-
apy seen in short-term studies is maintained in the long 
term (52–102 weeks) [33, 48].
In addition, the data from the studies in Asian patients 
with T2DM suggest that dapagliflozin is effective in that 
population [25, 33, 48]. More recent data support simi-
lar efficacy of dapagliflozin in white, black and Hispanic 
patients, suggesting its use may be beneficial irrespective 
of race [49].
Efficacy as add‑on or combination therapy
A number of randomized, double-blind, placebo-con-
trolled studies in patients with T2DM have evaluated the 
efficacy of dapagliflozin as adjunctive therapy with met-
formin [28, 47, 50–57] and insulin [58–61].
Glycemic efficacy and body weight data from key stud-
ies of dapagliflozin add-on/combination therapy with 
metformin or insulin are presented in Table 2. Dapagliflo-
zin is associated with clinically and statistically significant 
improvements in glycemic control and reductions in body 
weight, compared with placebo, when added to concur-
rent metformin or insulin therapy. Mean adjusted changes 
from baseline HbA1c ranged from −0.39 to −0.96 % in the 
primary studies, compared with +0.02 to −0.39 for pla-
cebo (Table 2). Mean adjusted changes from baseline body 
weight with dapagliflozin ranged from −0.90 to −5.05 kg 
in the primary studies, compared with +0.4 to −1.55 kg 
for placebo (Table 2). Changes in body weight associated 
with dapagliflozin primarily result from changes in fat 
mass (mediated by glycosuria), rather than fluid: accord-
ing to Bolinder et al., after 102 weeks reductions in total 
body fat mass were −2.80 kg (95 % CI −3.67, −1.93) in 
the dapagliflozin group, compared with −1.46 kg (95 % CI 
−2.25, −0.68) in the placebo group [52].
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In addition to placebo-controlled trials, dapagliflo-
zin was compared with glipizide as add-on therapy to 
concurrent metformin [53, 54, 56]. At 52  weeks, gly-
cemic efficacy was similar with dapagliflozin (change 
from baseline HbA1c −0.52  %) and glipizide (−0.52  %), 
but dapagliflozin produced significant benefits in body 
weight reduction (−3.2  kg versus +1.2  kg, respectively; 
P  <  0.0001), proportion of patients achieving ≥5  % 
body weight reduction (33.3 versus 2.5  %, respectively; 
P  <  0.0001) and proportion of patients experiencing 
hypoglycemia (3.5 versus 40.8 %, respectively; P < 0.0001) 
[53]. Long-term data from the extension of this study 
to 104  weeks [54] and 208  weeks [56] showed that, 
compared with glipizide, dapagliflozin is associated with 
sustained glycemic efficacy, greater reductions in body 
weight and systolic blood pressure, and lower frequency 
of hypoglycemia (Table 2).
Dapagliflozin as an add-on or in combination with 
other antidiabetic agents also consistently produced 
reductions in blood pressure [37, 39, 40].
The results of longer-term extension studies demon-
strate that the glycemic and body weight improvements 
with dapagliflozin are maintained after up to 4  years of 
follow-up. Mean adjusted changes from baseline HbA1c 
at the end of the extension studies ranged from −0.30 
to −0.82  % with dapagliflozin, compared with −0.10 to 
Table 1 Glycemic efficacy of dapagliflozin when used as monotherapy in patients with type 2 diabetes mellitus
a.m. morning, HbA1c, glycosylated hemoglobin
* P < 0.01 vs. placebo, ** P < 0.001 vs. placebo, †P < 0.0001 vs. placebo
Study Intervention Mean change from baseline HbA1c, %
List et al. [45] Placebo (n = 54) −0.18
Dapagliflozin 2.5 mg (n = 59) −0.71**
Dapagliflozin 5 mg (n = 58) −0.72**
Dapagliflozin 10 mg (n = 47) −0.85**
Dapagliflozin 20 mg (n = 59) −0.55*
Dapagliflozin 50 mg (n = 56) −0.90**
Metformin XR 750/1500 mg (n = 56) −0.73
Ferrannini et al. [43] Placebo (n = 75) −0.23
Dapagliflozin 2.5 mg a.m. (n = 65) −0.58
Dapagliflozin 5 mg a.m. (n = 64) −0.77**
Dapagliflozin 10 mg a.m. (n = 70) −0.89†
Dapagliflozin 2.5 mg evening (n = 67) −0.83
Dapagliflozin 5 mg evening (n = 68) −0.79
Dapagliflozin 10 mg evening (n = 76) −0.79
Bailey et al. [42] Placebo (n = 68) 0.02
Dapagliflozin 1 mg (n = 72) −0.68†
Dapagliflozin 2.5 mg (n = 74) −0.72†
Dapagliflozin 5 mg (n = 68) −0.82†
Henry et al. [47] Dapagliflozin 5 mg (n = 203) −1.19
Metformin XR 2000 mg (n = 201) (study 1) −1.35
Dapagliflozin 10 mg (n = 219) −1.45
Metformin XR 2000 mg (n = 208) (study 2) −1.44
Kaku et al. [46] Placebo (n = 54) 0.37
Dapagliflozin 1 mg (n = 59) −0.12**
Dapagliflozin 2.5 mg (n = 56) −0.11**
Dapagliflozin 5 mg (n = 58) −0.37**
Dapagliflozin 10 mg (n = 52) −0.44**
Ji et al. [44] Placebo (n = 132) −0.29
Dapagliflozin 5 mg (n = 128) −1.04
Dapagliflozin 10 mg (n = 133) −1.11
Kaku et al. [25] Placebo (n = 87) −0.06
Dapagliflozin 5 mg (n = 86) −0.41†
Dapagliflozin 10 mg (n = 88) −0.45†
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Table 2 Glycemic efficacy of dapagliflozin when used in combination therapy in patients with type 2 diabetes mellitus
Study Intervention Mean change from baseline HbA1c, % Mean change from baseline bodyweight 
(kg)
To end of main study To end of extension To end of main study To end of extension
Metformin studiesa
 Bailey et al. [50] Placebo (n = 137; 73) −0.30 0.02 −0.9 1.4
 Bailey et al. [51] (24 weeks; 
102 weeks)
Dapagliflozin 2.5 mg 
(n = 137; 82)
−0.67† −0.48† −2.2‡ −1.1‡
Dapagliflozin 5 mg 
(n = 137; 89)
−0.70‡ −0.58‡ −3.0‡ −1.7‡
Dapagliflozin 10 mg 
(n = 135; 95)
−0.84‡ −0.78‡ −2.9‡ −1.7‡
 Nauck et al. [53] Dapagliflozin ≤10 mg 
(n = 400; 161)
−0.52 −0.10 −3.2‡ −4.0
 Del Prato et al. [56] 
(52 weeks; 4 years)
Glipizide ≤20 mg 
(n = 401; 141)
−0.52 0.2 1.4 1.1
 Bolinder et al. [28] Placebo (n = 91; 49) −0.10 −0.12 −0.88‡ −2.12
 Bolinder et al. [52] 
(24 weeks; 2 years)
Dapagliflozin 10 mg 
(n = 89; 60)
−0.39‡ −0.30 −2.96 −4.54
 Matthaei et al. [57] Placebo (n = 108) −0.17 – −0.6 –
Dapagliflozin 10 mg 
(n = 108)
−0.86‡ – −2.7‡ –
 Schumm-Draeger et al. [55]Placebo (n = 101) −0.30 – −1.04 –
Dapagliflozin 2.5 mg bd 
(n = 100)
−0.52* – −2.84‡ –
Dapagliflozin 10 mg bd 
(n = 99)
−0.65‡ – −3.2‡ –
Dapagliflozin 10 mg od 
(n = 99)
−0.59† – −2.76‡ –
Insulin studiesb
 Zhang et al. [60] Placebo (n = 49) −0.20 – −0.95 –
 Intensive insulin ther-
apy ± insulin sensitizers 
at baseline
(patients with early-stage 
disease)
Dapagliflozin 10 or 20 mg 
(n = 102)
−0.70† (10 mg) – −2.00 (10 mg) –
(patients with early-stage 
disease)
−0.50† (20 mg) −2.50 (20 mg)
Placebo (n = 14) 0 – −1.55 –
(patients with late-stage 
disease)
Dapagliflozin 10 or 20 mg 
(n = 44)
−0.60† (10 mg) – −4.30 (10 mg) –
(patients with late stage 
disease)
−0.80† (20 mg) −5.05 (20 mg)
 Wilding et al. [58, 61] Placebo (n = 193; 108) −0.39 −0.43 0.4 1.8
 Insulin therapy ± oral 
antihyperglycemic drugs 
at baseline (24 weeks; 
2 years)
Dapagliflozin 2.5 mg 
(n = 202; 134)
−0.79† −0.64* −0.9† −1.0‡
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−0.43 for placebo (Table  2). Meanwhile, mean adjusted 
changes from baseline body weight ranged from −1.0 
to −4.54  kg with dapagliflozin, compared with +1.8 to 
−2.12 kg for placebo (Table 2).
The effects of dapagliflozin have also been evaluated in 
add-on or combination with the dipeptidyl peptidase-4 
inhibitor sitagliptin, the sulfonylurea glimepiride, and the 
thiazolidinedione pioglitazone. In patients inadequately 
controlled on sitagliptin with or without metformin, add-
on therapy with dapagliflozin 10 mg provided additional 
clinical benefit without increasing hypoglycemia events 
[62].
In patients with inadequate glycemic control with 
glimepiride, dapagliflozin (at the 5 or 10  mg dose) sig-
nificantly improved HbA1c and significantly reduced 
body weight, compared with glimepiride alone [63]. 
At 24  weeks, the mean adjusted changes from baseline 
HbA1c were −0.13  % for placebo versus −0.63  % with 
dapagliflozin 5 mg and −0.82 % with dapagliflozin 10 mg, 
respectively (both P < 0.0001 vs. placebo). Corresponding 
mean adjusted changes from baseline body weight were 
−0.72, −1.56 and −2.26  kg, respectively, for placebo, 
dapagliflozin 5  mg (P  <  0.001 vs. placebo), and 10  mg 
(P < 0.0001 vs. placebo), respectively. There was a higher 
incidence of hypoglycemia in the dapagliflozin group 
(7.1–7.9 % vs. 4.8 %, respectively), as has been observed 
when dapagliflozin is added to sulfonylureas in other 
studies, and no patient discontinued treatment because 
of hypoglycemia.
Finally, in patients not adequately controlled on 
pioglitazone, dapagliflozin further lowered HbA1c and 
lessened pioglitazone-associated weight gain [64]. At 
24  weeks, the mean adjusted changes from baseline 
HbA1c were −0.42  % for placebo versus −0.82  % with 
dapagliflozin 5  mg (P  <  0.001 vs. placebo) and −0.97  % 
with dapagliflozin 10 mg (P < 0.0001 vs. placebo) respec-
tively. Patients in the pioglitazone alone group gained 
significantly more body weight than those in the piogl-
itazone plus dapagliflozin groups. At 24 weeks, the mean 
adjusted changes from baseline body weight were +1.64, 
+0.09 and −0.14  kg, respectively, for placebo, dapagli-
flozin 5 mg, and dapagliflozin 10 mg (both P < 0.001 vs. 
placebo). By 48 weeks, patients in the pioglitazone alone 
group had gained a mean of 2.99 kg from baseline, com-
pared with 1.35 kg for dapagliflozin 5 mg, and 0.69 kg for 
dapagliflozin 10 mg, respectively. However, dapagliflozin 
is not recommended for use in patients concomitantly 
treated with pioglitazone [65].
Longer-term extension phases of these trials demon-
strate that reductions in HbA1c, FPG, and bodyweight are 
maintained during follow-up periods of up to 4 years [50, 
52, 53, 56, 58, 61–64, 66].
A recent meta-analysis designed to evaluate whether 
dapagliflozin is synergistic with other antidiabetic 
agents without affecting body weight concluded that 
dapagliflozin in combination with conventional antidia-
betic drugs (metformin, glimepiride, pioglitazone, and 
metformin/sitagliptin) improved glycemic control (the 
overall effect size was −0.52 %) and reduced weight gain 
in patients with T2DM (the effect size was −2.10  kg) 
[39]. Twelve randomized controlled trials with a total of 
3986 participants were included in the glycemic control 
analysis (1996 dapagliflozin; 1990 controls), and 4008 in 
the body weight analysis (2005 dapagliflozin; 2003 con-
trols). Follow-up durations ranged from 12 to 208 weeks 
[56].
Of interest, dapagliflozin 10  mg treatment signifi-
cantly improved glycemic control and reduced body 
weight both in 151 early-stage and in 58 late-stage 
patients with T2DM, reflecting the usefulness of dapa-
gliflozin as monotherapy in patients in the early stage of 
T2DM, and as add-on or combination therapy in late-
stage patients on high doses of insulin plus oral insulin 
sensitizers [60].
Key studies and their extensions
bd twice daily, HbA1c glycosylated hemoglobin, od once daily
* P < 0.05 vs. placebo, ** P < 0.01 vs. placebo, †P < 0.001 vs. placebo, ‡P < 0.0001 vs. placebo. Not all studies reported P values
a All patients were receiving metformin therapy
b All patients were receiving insulin therapy
Table 2 continued
Study Intervention Mean change from baseline HbA1c, % Mean change from baseline bodyweight 
(kg)
To end of main study To end of extension To end of main study To end of extension
Dapagliflozin 5 or 10 mg 
(n = 211; 129)
−0.89† −0.82† −1.0† −1.0‡
Dapagliflozin 10 mg 
(n = 194; 142)
−0.96† −0.78† −1.6† −1.5‡
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To date, dapagliflozin in combination with glucagon-
like peptide 1 (GLP-1) analogs is still being studied 
(https://clinicaltrials.gov/ct2/show/NCT02229396).
Dapagliflozin and β‑cell function
Improvements in β-cell function have been demon-
strated for dapagliflozin using the homeostasis model 
assessment of β-cell function (HOMA β-cell) [40, 65], 
possibly resulting from a reduction in glucose toxicity. 
This hypothesis has been examined in a small study that 
demonstrated that lowering of plasma glucose concentra-
tion by dapagliflozin-induced glycosuria improved β-cell 
function and insulin resistance in patients with T2DM 
[13]. Importantly, these results demonstrate that the glu-
cotoxic effect of chronic hyperglycemia on β-cell function 
in T2DM is, at least in part, reversible [13]. The authors 
theorized that, as dapagliflozin has not been shown to act 
directly on β-cell function, improvement in β-cell func-
tion was related to amelioration of hyperglycemia, that is, 
by reversing glucose toxicity [13]. Further investigation is 
warranted.
Nephroprotection
In addition to improved glycemic control, reductions in 
serum uric acid levels and tubular glucose toxicity and 
attenuation of diabetes-related hyperfiltration suggest 
that SGLT2 inhibitors may be able to influence renal 
hemodynamics independently of glucose reduction [27, 
40, 67, 68]. However, the effect of dapagliflozin and other 
SGLT2 inhibitors in slowing the development and pro-
gression of diabetic nephropathy is currently speculative, 
although preliminary data on the effect of dapagliflozin 
in patients already treated with renin-angiotensin sys-
tem blockers have recently been presented, showing that 
dapagliflozin reduced albuminuria without increasing 
renal adverse events [69, 70].
Safety and tolerability
The safety of dapagliflozin as monotherapy and as add-on 
therapy to existing antidiabetic treatment in patients with 
T2DM has been evaluated in multiple randomized con-
trolled trials and has been assessed in five comprehensive 
reviews or meta-analyses [37–40, 71].
A pooled safety analysis of 12 placebo-controlled phase 
II/III clinical trials of up to 102  weeks duration that 
assessed dapagliflozin at doses of 2.5, 5, and 10 mg once 
daily in a total of more than 4000 patients has recently 
been published [71]. The analysis was supplemented 
by data from an active comparator trial, from a trial in 
patients with moderate renal impairment, and from five 
additional studies that were ongoing at the time of analy-
sis, giving a total of 19 studies. In general, the analyses 
were performed for patients who received at least one 
dose of study medication during the double blind phase 
of the study. The patient populations in the pooled anal-
yses were representative of the general population of 
patients with T2DM.
The majority (>90  %) of treatment-emergent adverse 
events (AEs) were mild-to-moderate in intensity, with-
out a discernible dose relationship. One or more AEs 
were reported by 61.7  % of dapagliflozin recipients and 
56.9  % of placebo recipients, and AEs were considered 
treatment-related in 17.3  % of dapagliflozin recipients 
and 13.3 % of the placebo group.
Hypoglycemia, urinary tract infections, vulvovaginitis/
balanitis and related genital infections, back pain, polyu-
ria, dysuria, and dyslipidemia were the most commonly 
reported AEs in the pooled dapagliflozin group (Table 3) 
[71]. In none of the studies did hypoglycemia lead to 
withdrawal, and it predominantly occurred when dapa-
gliflozin was used with a sulfonylurea or insulin (Table 4). 
Similar proportions of dapagliflozin and placebo recipi-
ents reported serious AEs (3.7 vs. 3.3  %, respectively) 
and AEs resulting in study discontinuation (2.8 vs. 2.5 %, 
respectively). The tolerability profile demonstrated in 
the short-term studies was maintained consistently in 
patients receiving long-term dapagliflozin treatment.
No substantial adverse effects on serum electrolytes, 
liver function, or renal function were reported [71]. In 
general, there was a transient decrease in eGFR during 
the first weeks of dapagliflozin treatment, followed by a 
return to baseline levels or higher. Overall, there was no 
evidence of new or worsening renal impairment, acute 
nephrotoxicity, or progression of diabetic nephropathy 
in dapagliflozin-treated patients at up to 2  years [71]. 
Recent findings from routine clinical practice confirm 
that dapagliflozin therapy is not associated with nephro-
toxicity [72].
Volume-related events, i.e. hypotension, dehydration 
and hypovolemia, were infrequent and none were seri-
ous, but occurred more often in the dapagliflozin group 
(0.8  %) compared with placebo (0.4  %) [71]. There was 
a higher risk of volume depletion events for dapagliflo-
zin compared with placebo in patients also receiving 
loop diuretics (6.1 vs. 1.8  %, respectively). Numerically 
higher rates of dyslipidemia with dapagliflozin versus 
placebo have been reported, with small elevations in 
total cholesterol, low-density lipoprotein cholesterol 
and high-density lipoprotein cholesterol, and reduc-
tions in triglycerides [71]. There are some reports about 
patients on SGLT2 inhibitor treatment developing dia-
betic ketoacidosis [73]. Although there are no published 
reports of ketoacidosis specifically with dapagliflo-
zin, it can be assumed that this is a class effect due to 
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inappropriate prescriptions in patients with insufficient 
insulin (either endogenous or exogenous) and in which 
ketoacidosis has been masked by concomitant euglycae-
mia [74]. The US Food and Drug Administration and the 
European Agency of Medicine are currently investigat-
ing this issue through an extensive review of all available 
data and will consider whether any changes are needed 
in the way these medicines are used in the US and EU 
[75].
Although investigation into the cardiovascular effects 
of dapagliflozin and other SGLT2 inhibitors is ongoing, 
the cardiovascular safety of dapagliflozin appears to be 
favorable. An independently-adjudicated meta-analysis of 
data from >9000 patients with T2DM suggests that dapa-
gliflozin does not increase cardiovascular risk in terms 
of MACE (major adverse cardiac events; a composite of 
cardiovascular death, non-fatal stroke, and non-fatal myo-
cardial infarction) versus placebo or active control [76]. 
No adverse impact on cardiovascular safety of dapagli-
flozin treatment, compared with placebo, was recently 
reported even in high-risk patients with pre-existing car-
diovascular disease and a history of hypertension [77]. 
Of interest, a multicenter, double blind, randomized, 
parallel group trial is underway (DECLARE-TIMI58 
study; https://clinicaltrials.gov/show/NCT01730534) to 
evaluate the possibility that dapagliflozin may have a ben-
eficial effect on the incidence of cardiovascular events in 
patients with T2DM and established cardiovascular dis-
ease or multiple risk factors.
Among some phase 2 and phase 3 trials in the dapa-
gliflozin development program there was a small excess 
in event rates for male bladder cancer and female breast 
cancer over rates expected of the age-matched diabetic 
population [71, 78]. However, the imbalance was not 
statistically significant, and the diagnosis of all breast 
and bladder cancers within 1 and 2 years, respectively, 
of starting dapagliflozin and the wide biological het-
erogeneity of, in particular, the bladder cancers argue 
against a single causative agent. Updated data gathered 
from an additional 21 trials to November 2013 did not 
find any imbalance of malignancies in dapagliflozin-
treated patients [78]. Nevertheless, although there are 
no indications of a statistically significantly increase 
in risk of cancer with dapagliflozin and it appears that 
early tumor diagnosis may be attributable to detection 
bias rather than as a result of a causal relationship, this 
issue, specifically regarding the risk of bladder cancer, 
will be further explored in ongoing dapagliflozin trials 
[71, 78]. Moreover, there have been no carcinogenicity 
or mutagenicity signals in the preclinical development 
program [65], and a recent study found that exposure 
of mice and rats to dapagliflozin for up to 2  years at 
levels greater than 100-fold and up to 186-fold human 
clinical exposure, respectively, did not increase bladder 
or mammary tumor rates, urinary bladder prolifera-
tive/preneoplastic lesions, or enhance tumor growth in 
murine models of human bladder transitional cell car-
cinoma, suggesting that dapagliflozin does not promote 
tumor growth [79].
In older patients (≥65 years), the incidence and nature 
of AEs was similar to that observed in the overall popula-
tion and in patients younger than 65 years [71].
Although there was a higher incidence of fractures 
reported among dapagliflozin compared with placebo 
recipients in a study of T2DM patients with moder-
ate renal impairment [35], there was no evidence for an 
imbalance in fracture rate of patients in the dapagliflozin 
and all control groups in the pooled safety data [71]. Fur-
thermore, dapagliflozin did not affect markers of bone 
Table 3 Incidence of  adverse events (percent patients) 
reported in  patients treated with  dapagliflozin 5  mg, 
dapagliflozin 10 mg, or placebo
Pooled data from 12 placebo-controlled phase II/III clinical studies. Modified 
with permission from Ptaszynska et al. [71]
a Major hypoglycemia requiring assistance or treatment and which, if left 
untreated may be life-threatening, occurred in 0.1 % of each of the dapagliflozin 
groups, and in 0.1 % of placebo recipients. Most hypoglycemic events were from 
add-on to insulin and add-on to sulfonylureas
b Vulvovaginitis/balanitis and related genital infections
Placebo Dapagliflozin
(N = 1393) 5 mg 
(N = 1145)
10 mg 
(N = 1193)
Hypoglycemiaa 7.0 10.9 10.2
Genital infectionb 0.9 5.7 4.8
Urinary tract infection 3.7 5.7 4.3
Back pain 3.2 3.1 4.2
Polyuria 1.7 2.9 3.8
Dysuria 0.7 1.6 2.1
Dyslipidemia 1.5 2.1 2.5
Table 4 Incidence of  hypoglycemia (percent patients) 
stratified by monotherapy and add‑on therapies
Pooled data from 12 placebo-controlled phase II/III clinical studies. Data from 
Ptaszynska et al. [71]
Placebo Dapagliflozin
5 mg 10 mg
Placebo-controlled studies 7.0 10.9 10.2
Monotherapy studies 2.0 2.2 2.9
Add-on combination plus metformin 3.1 – 3.1
Plus pioglitazone 0.7 2.1 0
Plus a sulfonylurea 4.8 6.9 7.3
Plus insulin 35.0 45.3 42.3
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formation and resorption, or bone mineral density, at 
week 50 of a placebo-controlled study in 182 female and 
male patients with T2DM [80].
The generally favorable and predictable tolerability pro-
file of dapagliflozin reported in this section is supported 
by the various meta-analyses and comprehensive reviews 
published to date [37–40, 71].
Dapagliflozin in type 1 diabetes mellitus
Although dapagliflozin is currently only approved for the 
treatment of T2DM, studies of its efficacy and safety in 
T1DM are ongoing (Table  5). A pilot study describing 
2  weeks of dapagliflozin treatment in 62 patients with 
T1DM showed dose-related reductions in glycemic varia-
bility, 24-h glucose and insulin requirement [81]. Patients 
with T1DM on stable insulin therapy were randomized to 
dapagliflozin 1, 2.5, 5, or 10  mg or placebo. Short-term 
tolerability was acceptable, and the pharmacokinetic 
profile was similar to that observed in studies in patients 
with T2DM, including dose-dependent increases in uri-
nary glucose excretion. Changes suggestive of improved 
glycemic control were observed, which will be further 
explored in larger trials of longer duration.
Conclusions
The SGLT2 inhibitors are a new class of antidiabetic 
agents with a unique, insulin-independent mechanism 
of action that depends only on plasma glucose and renal 
function. SGLT2 inhibitors offer benefits beyond glyce-
mic control, including modest reductions in body weight 
and blood pressure and improved insulin sensitivity and 
β-cell function.
Dapagliflozin is an orally available SGLT2 inhibitor with 
an insulin independent mechanism of action and a lower 
risk of hypoglycemia than with conventional antidiabetic 
agents such as sulfonylureas and insulin. Dapagliflozin 
is effective as monotherapy or as an add-on to insulin or 
any other oral antidiabetic agent, and reduces both body 
weight and blood pressure. Clinical trials published to 
date have shown that dapagliflozin is effective and safe in 
patients with T2DM, both as monotherapy and in com-
bination with other glucose-lowering agents, and recent 
data reporting 4-years’ clinical experience support these 
findings [56]. Moreover, recent findings have demon-
strated a remarkably rapid action of dapagliflozin, with 
reductions in FPG levels within 1 week of treatment [77].
Dapagliflozin is effective in both early and late stages of 
T2DM, despite differences in disease status and concom-
itant medications, suggesting that the insulin-independ-
ent mechanism of action of dapagliflozin could make it a 
suitable treatment option throughout the different stages 
of clinical progression of T2DM.
Currently, dapagliflozin may be considered a second-
line agent to treat patients with T2DM and has the 
potential to provide a first-line option, particularly for 
patients with contraindications or lack of glycemic con-
trol on metformin, the conventional first-line agent. Due 
to the frequency of genital infections, possibly related to 
induction of glycosuria, caution is indicated in patients 
prone to these types of infections. Long-term data on 
cardiovascular and mortality outcomes of dapagliflozin 
are awaited.
Dapagliflozin is also expected to be effective as an 
adjunct to insulin for the treatment of T1DM, and may 
be particularly appropriate in patients with T1DM 
treated with high doses of insulin or who need weight 
loss. However, clinical trials in patients with T1DM are 
still ongoing.
Table 5 Trials of dapagliflozin in patients with type 1 diabetes mellitus currently registered on ClinicalTrials.gov
a Henry et al. [81]
ClinicalTrials.gov 
identifier
Phase (status) Study design Dose Main objectives
NCT02325206 I (Recruiting) Randomized, placebo controlled, 
crossover
10 mg (single dose) Safety and pharmacokinetics; degree 
of insulin dose reduction after 24-h
NCT01498185a II (Completed) Randomized, double-blind, placebo 
controlled
1, 2.5, 5, 10 mg × 14 days Safety, change from baseline mean 
plasma glucose, pharmacokinetics 
and pharmacodynamics
NCT02268214 III (Recruiting) Randomized, double blind, placebo 
controlled
5 or 10 mg × 52 weeks Efficacy (change in HbA1c at week 24; 
change from baseline insulin dose, 
metabolic parameters.
NCT02211742 IV (Recruiting) Randomized, double-blind, crossover 10 mg × 3 days Effect of dapagliflozin on fasting glu-
cose homeostasis and postprandial 
glucose excursions in male patients
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